title: A case report of isolated lymphadenopathy revealing localized leishmanial lymphadenopathy in an asthenic 25-year-old man.
abstract: BACKGROUND
  Visceral leishmaniasis (VL) is endemic in large areas of the tropics, the subtropics, and the Mediterranean basin. Besides classical VL presentation, exceptional cases of a limited form of VL have been reported. Here we describe the challenges of diagnosis and management of this intriguing entity.
  
  
  METHODS
  A 25-year-old French Caucasian man presented with marked asthenia that had lasted 6 months and was strictly isolated except for a 2-cm left cervical lymphadenopathy. The rest of the clinical examination and extensive biological exploration were unremarkable.Histological examination of the cervical lymphadenopathy showed a reactive lymphoid hyperplasia with granulomatous organization associated with small particles in the cytoplasm of epithelioid histiocytes and giant cells evocative of Leishman-Donovan bodies. Polymerase chain reaction (PCR) performed on the tissue confirmed the presence of Leishmania donovani/infantum DNA. Direct examination of a bone marrow aspiration, together with blood and bone marrow PCR, did not find other evidence for VL. Serology for leishmaniasis was unreactive. Extensive work-up for other causes of granulomatous lymphadenitis was negative. A diagnosis of localized leishmanial lymphadenopathy was made. Intravenous liposomal amphotericin B (20 mg/kg in five infusions) was initiated and well tolerated. Asthenia disappeared promptly and the patient fully recovered.
  
  
  CONCLUSIONS
  Localized lymph node enlargement because of leishmanial infection should be included in the differential diagnosis of lymphadenopathy of unknown origin in patients who stayed or visited, even a long time ago and for a short period, endemic areas for leishmaniasis such as the Mediterranean basin. Fine-needle aspiration cytology and/or PCR for Leishmania sp of the lymphadenopathy might contribute to the diagnosis. A low-dose liposomal amphotericin B treatment might be effective, and deserves further study.
authors.affiliation: Department of Pathology, Institut Universitaire du Cancer Department of Parasitology, Toulouse University Hospital INSERM, Centre de Physiopathologie Toulouse-Purpan, Toulouse Department of Pathology, Nice University Hospital, Nice Department of Infectious and Tropical Diseases, Toulouse University Hospital CRCT INSERM U1037, Toulouse Laboratoire d'Excellence Toulouse Cancer LABEX-TOUCAN, France.
authors.forename: Quentin
authors.initials: Q
authors.lastname: Hurlot
authors.forename: Judith
authors.initials: J
authors.lastname: Fillaux
authors.forename: Camille
authors.initials: C
authors.lastname: Laurent
authors.forename: Antoine
authors.initials: A
authors.lastname: Berry
authors.forename: Paul
authors.initials: P
authors.lastname: Hofman
authors.forename: Bruno
authors.initials: B
authors.lastname: Marchou
authors.forename: Pierre
authors.initials: P
authors.lastname: Delobel
authors.forename: Pierre
authors.initials: P
authors.lastname: Brousset
authors.forename: Guillaume
authors.initials: G
authors.lastname: Martin-Blondel
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D044963:Biopsy, Fine-Needle; D003937:Diagnosis, Differential; D006801:Humans; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000175:diagnosis*; D000072281:Lymphadenopathy / Q000469:parasitology*; D008297:Male; D016133:Polymerase Chain Reaction
chemical_list: D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B